Cellebrite DI Ltd. (CLBT) Income Statement
CLBT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCLBT revenue and net income
Where CLBT's revenue goes
2025Each bar shows an amount and its share of revenue. CLBT kept 16.5% of revenue as net income.
CLBT profit margins
CLBT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +18.6% | +20.7% | +19.5% | — |
| Gross profit | +18.3% | +22.1% | +20.6% | — |
| Operating income | +16.8% | +299.3% | +48.5% | — |
| Net income | — | −13.4% | +68.4% | — |
| EPS (diluted) | +19.0% | +22.8% | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CLBT quarterly EPS vs estimates
Cellebrite DI beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 11, 2026 (estimate $0.12).
CLBT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $475.7M | $401.2M | $325.1M | $270.7M | $246.2M | $194.9M | $171.9M |
| Cost of revenue | $75.2M | $62.6M | $53.2M | $50.7M | $42.6M | $37.9M | $35.8M |
| Gross profit | $400.5M | $338.6M | $271.9M | $219.9M | $203.7M | $157.0M | $136.0M |
| Research & development | $113.9M | $98.4M | $84.4M | $80.6M | $65.5M | $54.4M | $46.6M |
| Sales, general & admin | $220.1M | $183.3M | $154.3M | $138.2M | $124.3M | $91.2M | $90.2M |
| Total operating expenses | $334.0M | $281.7M | $238.6M | $218.9M | $189.9M | $147.8M | $137.6M |
| Operating income | $66.5M | $56.9M | $33.2M | $1.0M | $13.8M | $9.2M | −$1.5M |
| Interest income | $23.9M | $18.2M | $8.9M | $1.6M | $68.5M | $2.2M | $2.9M |
| Interest expense | $523,000 | $349.8M | $141,000 | $149,000 | $153,000 | $1.4M | $352,000 |
| Income before taxes | $90.7M | −$276.0M | −$75.6M | $120.8M | $82.3M | $11.4M | $1.4M |
| Income taxes | $12.4M | $7.0M | $5.5M | −$45,000 | $10.9M | $5.6M | $3.3M |
| Net income | $78.3M | −$283.0M | −$81.1M | $120.8M | $71.4M | $5.8M | −$1.9M |
| EBITDA | $103.1M | −$265.3M | −$65.4M | $130.1M | $89.5M | $17.3M | $5.6M |
| EPS (diluted) | $0.50 | $0.42 | $0.29 | $0.27 | $0.38 | −$0.20 | −$0.02 |
| Gross margin | 84.2% | 84.4% | 83.6% | 81.3% | 82.7% | 80.6% | 79.2% |
| Operating margin | 14.0% | 14.2% | 10.2% | 0.4% | 5.6% | 4.7% | −0.9% |
| Net margin | 16.5% | −70.5% | −24.9% | 44.6% | 29.0% | 3.0% | −1.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $131.1M | $128.3M | $128.8M | $126.0M | $113.3M | $107.5M | $109.0M | $106.9M | $95.7M | $89.6M | $93.0M | $84.2M |
| Cost of revenue | $25.2M | $22.4M | $19.7M | $20.3M | $17.7M | $17.5M | $17.6M | $15.4M | $16.3M | $13.3M | $14.9M | $12.9M |
| Gross profit | $105.9M | $105.9M | $109.1M | $105.7M | $95.6M | $90.1M | $91.4M | $91.4M | $79.5M | $76.3M | $78.1M | $71.3M |
| Research & development | $36.0M | $35.9M | $29.9M | $28.1M | $28.6M | $27.3M | $25.6M | $25.9M | $23.7M | $23.2M | $21.8M | $20.5M |
| Sales, general & admin | $63.0M | $60.9M | $58.5M | $58.6M | $52.6M | $50.5M | $50.1M | $46.0M | $43.3M | $43.9M | $41.3M | $37.4M |
| Total operating expenses | $98.3M | $96.8M | $88.3M | $86.7M | $81.2M | $77.8M | $75.7M | $72.0M | $67.0M | $67.1M | $63.1M | $57.8M |
| Operating income | $7.6M | $9.1M | $20.8M | $19.0M | $14.4M | $12.3M | $15.7M | $19.4M | $12.5M | $9.2M | $15.0M | $13.5M |
| Interest income | $4.2M | — | — | — | $6.4M | — | — | — | — | — | — | — |
| Interest expense | — | — | — | — | — | — | $1.3M | $224.0M | $34.5M | $78.6M | $27.3M | $6.6M |
| Income before taxes | $11.2M | $13.6M | $26.3M | $24.3M | $20.8M | $19.3M | $19.9M | −$204.5M | −$22.0M | −$69.3M | −$12.3M | $6.8M |
| Income taxes | $4.8M | $2.7M | $5.0M | $4.1M | $1.3M | $1.9M | $628,000 | $2.6M | $1.8M | $2.0M | $2.3M | $349,000 |
| Net income | $6.4M | $10.9M | $21.3M | $20.2M | $19.5M | $17.4M | $19.3M | −$207.1M | −$23.8M | −$71.4M | −$14.6M | $6.5M |
| EBITDA | $16.5M | $20.6M | $49.5M | $27.0M | $30.5M | $22.0M | −$314.4M | $22.1M | $15.1M | $11.9M | −$91.0M | $15.9M |
| EPS (diluted) | $0.05 | $0.12 | $0.14 | $0.14 | $0.12 | $0.10 | $0.10 | $0.14 | $0.10 | $0.08 | $0.12 | $0.09 |
| Gross margin | 80.8% | 82.5% | 84.7% | 83.9% | 84.4% | 83.7% | 83.8% | 85.5% | 83.0% | 85.2% | 84.0% | 84.7% |
| Operating margin | 5.8% | 7.1% | 16.2% | 15.1% | 12.7% | 11.4% | 14.4% | 18.2% | 13.0% | 10.3% | 16.1% | 16.0% |
| Net margin | 4.9% | 8.5% | 16.5% | 16.0% | 17.2% | 16.2% | 17.7% | −193.8% | −24.9% | −79.7% | −15.7% | 7.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CLBT's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CLBT financial results
In fiscal year 2025 (ended December 31, 2025), Cellebrite DI reported revenue of $475.7 million, up 18.6% from the year before. It had net income of $78.3 million, a net profit margin of 16.5%. Diluted earnings per share came to $0.50. Over five years revenue grew at an average rate of 19.5% a year.
See the CLBT stock overview for the latest quote and news, or the CLBT chart for price history and technical indicators.
CLBT income statement FAQ
What is Cellebrite DI's annual revenue?
Cellebrite DI reported total revenue of $475.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 18.6% from $401.2 million the previous year.
Is Cellebrite DI profitable?
Yes. Cellebrite DI reported net income of $78.3 million in fiscal 2025, a net profit margin of 16.5%; its operating margin was 14.0%.
What is Cellebrite DI's gross margin?
Cellebrite DI's gross margin was 84.2% in fiscal 2025: for every $100 of revenue, Cellebrite DI kept $84 after the direct cost of its products and services.
How much does Cellebrite DI spend on research and development?
Cellebrite DI spent $113.9 million on research and development in fiscal 2025, 23.9% of revenue.
How fast is Cellebrite DI growing?
Revenue grew 19.5% a year on average over the last five fiscal years, from $194.9 million to $475.7 million.
What are Cellebrite DI's earnings per share?
Cellebrite DI earned $0.50 per diluted share in fiscal 2025, compared with $0.42 a year earlier.
When will Cellebrite DI report its next earnings?
Cellebrite DI is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Cellebrite DI's fiscal year end?
Cellebrite DI's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.